SRPT insider trading
NasdaqGS HealthcareSarepta Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Company website: www.sarepta.com
SRPT insider activity at a glance
FilingIQ has scored 646 insider transactions for SRPT since Feb 27, 2015. The most recent filing in our index is dated Mar 12, 2026.
Across the full history, 40 open-market purchases
and 98 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SRPT insider trades is 56.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Top insiders trading SRPT
13F funds holding SRPT
Frequently asked
- How many insider trades does FilingIQ track for SRPT?
- FilingIQ tracks 646 Form 4 insider transactions for SRPT (Sarepta Therapeutics, Inc.), covering filings from Feb 27, 2015 onwards. 28 of those were filed in the last 90 days.
- Are SRPT insiders net buyers or net sellers?
- Across the full Form 4 history for SRPT, 40 transactions (6%) were open-market purchases and 98 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SRPT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SRPT in?
- Sarepta Therapeutics, Inc. (SRPT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.95B.
Methodology & sources
Every SRPT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.